Founded in 2024, Polar NanoPharma is dedicated to addressing the key challenges in oncology drug delivery. Our goal is to improve patient outcomes with cutting-edge solutions.
Ecostratar nanotecnology platform: Innovation in polymeric nanomedicines
At the heart of our innovation is the reinvention of polycarbamate-polyurea (PCPU) polymer chemistry, integrated into the cutting-edge Ecostratar nanotechnology platform. By designing prepolymers with advanced self-emulsifying and self-stratifying properties, we have developed a system that effectively solubilizes and protects drugs in PCPU aqueous dispersions. Our nanoparticle systems are capable to accumulate and release its cargo, triggered by tumor-related physiological changes. Our strategic collaborations, allow us to show tolerability and efficacy of our systems in vivo animal studies, outperforming conventional drug formulations.
Over 30 Years of R&D Experience in Polymer Chemistry and Drug Delivery
With over three decades of research and development in polymer chemistry and drug delivery systems, our team is committed to applying the Ecostratar technology to oncological treatments. We are focused on advancing cancer diagnostics and therapeutics through nanomedical innovations, paving the way for more effective, targeted treatments. At Polar NanoPharma, our mission is to create transformative medicines that benefit patients worldwide.